Brent Egan to Double-Blind Method
This is a "connection" page, showing publications Brent Egan has written about Double-Blind Method.
Connection Strength
0.355
-
Effects of a Six-Month Multi-Ingredient Nutrition Supplement Intervention of Omega-3 Polyunsaturated Fatty Acids, vitamin D, Resveratrol, and Whey Protein on Cognitive Function in Older Adults: A Randomised, Double-Blind, Controlled Trial. J Prev Alzheimers Dis. 2018; 5(3):175-183.
Score: 0.112
-
Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL. Curr Med Res Opin. 2004 Dec; 20(12):1909-17.
Score: 0.045
-
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. J Hypertens. 2014 Feb; 32(2):251-9.
Score: 0.021
-
Ketanserin's sympatholytic and serotonin2-receptor blocking actions precede the hypotensive effects. J Hum Hypertens. 1994 Jan; 8(1):59-64.
Score: 0.021
-
Improved baroreflex sensitivity in elderly hypertensives on lisinopril is not explained by blood pressure reduction alone. J Hypertens. 1993 Oct; 11(10):1113-20.
Score: 0.021
-
Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992 Nov 15; 70(15):1347-52.
Score: 0.020
-
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients. J Clin Hypertens (Greenwich). 2011 Oct; 13(10):731-8.
Score: 0.018
-
Potential deleterious impact of dietary salt restriction on cardiovascular risk factors. Klin Wochenschr. 1991; 69 Suppl 25:45-50.
Score: 0.017
-
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial. Cardiovasc Ther. 2010 Dec; 28(6):344-9.
Score: 0.017
-
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J Clin Hypertens (Greenwich). 2008 Jun; 10(6):436-42.
Score: 0.014
-
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008 Mar; 26(3):589-99.
Score: 0.014
-
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006 Apr 20; 354(16):1685-97.
Score: 0.012
-
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study. Am J Hypertens. 2005 Jul; 18(7):980-5.
Score: 0.012
-
Trial of preventing hypertension: design and 2-year progress report. Hypertension. 2004 Aug; 44(2):146-51.
Score: 0.011